This paper describes a randomized, double-blind, placebo-controlled intervention study conducted by researchers from the Leibniz University Hannover in Germany to evaluate the effects of a low moncacolin K dose and folic acid on plasma lipids and homocysteine levels, respectively. The results of their analyses were published in the journal Nutrition Research.
Hypercholesterolemia and elevated homocysteine concentrations are associated with cardiovascular risk.
The researchers hypothesized that a low monacolin K dose could reduce low-density lipoprotein–cholesterol (LDL-C) and other plasma lipids.
They also tested the ability of folic acid to lower homocysteine; folic acid was included in the study preparation.
They randomly assigned 142 nonstatin-treated participants with hypercholesterolemia (LDL-C ? 4.14 ? 5.69 mmol/L) to either the treatment group or the placebo group.
Participants of the treatment group consumed 3 mg monacolin K and 200 micrograms (ug) folic acid per day.
The researchers found a significant (P < .001) reduction in LDL-C (?14.8 percent), total cholesterol (?11.2 percent), and homocysteine (?12.5 percent) in the treatment group after 12 weeks.
They also noted that 51 percent of the participants treated with RYR achieved the limit of LDL-C (<4.14 mmol/L) advised, and 26 percent reached the threshold level of homocysteine (<10 umol/L).
Meanwhile, they observed no significant changes in the placebo group; they reported no intolerance or any serious adverse events.
Based on these results, the researchers concluded that taking a low dose of 3 mg monacolin K from RYR daily reduces the concentration of LDL-C, which is a risk factor for cardiovascular diseases.
Heinz T, Schuchardt JP, Möller K, Hadji P, Hahn A. LOW DAILY DOSE OF 3 MG MONACOLIN K FROM RYR REDUCES THE CONCENTRATION OF LDL-C IN A RANDOMIZED, PLACEBO-CONTROLLED INTERVENTION. Nutrition Research. October 2016;36(10):1162–1170. DOI: 10.1016/j.nutres.2016.07.005